Forte Biosciences (FBRX) Liabilities and Shareholders Equity (2016 - 2026)

Forte Biosciences (FBRX) has 11 years of Liabilities and Shareholders Equity data on file, last reported at $67.2 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 41.64% year-over-year to $67.2 million in Q1 2026; TTM through Mar 2026 was $354.9 million, a 131.88% increase from a year earlier, with the FY2025 full-year figure at $82.8 million, up 34.47% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $67.2 million, down from $82.8 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for FBRX reached as high as $107.8 million in Q2 2025 and fell as low as $17.9 million in Q3 2024.
• Historically, Liabilities and Shareholders Equity has averaged $50.8 million across 5 years, with a median of $42.0 million in 2022.
• Across the five-year window, Liabilities and Shareholders Equity plunged 62.52% in 2024 and soared 441.01% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $42.0 million in 2022, then decreased by 7.18% to $39.0 million in 2023, then soared by 57.93% to $61.6 million in 2024, then jumped by 34.47% to $82.8 million in 2025, then decreased by 18.79% to $67.2 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $67.2 million in Q1 2026, $82.8 million in Q4 2025, and $97.1 million in Q3 2025.